Biohaven Non Currrent Assets Other vs Current Deferred Revenue Analysis
| BHVN Stock | USD 38.45 1.37 3.69% |
Biohaven Pharmaceutical financial indicator trend analysis is way more than just evaluating Biohaven Pharmaceutical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biohaven Pharmaceutical is a good investment. Please check the relationship between Biohaven Pharmaceutical Non Currrent Assets Other and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
Non Currrent Assets Other vs Current Deferred Revenue
Non Currrent Assets Other vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biohaven Pharmaceutical Non Currrent Assets Other account and Current Deferred Revenue. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Biohaven Pharmaceutical's Non Currrent Assets Other and Current Deferred Revenue is 0.59. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Biohaven Pharmaceutical Holding, assuming nothing else is changed. The correlation between historical values of Biohaven Pharmaceutical's Non Currrent Assets Other and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Biohaven Pharmaceutical Holding are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Non Currrent Assets Other i.e., Biohaven Pharmaceutical's Non Currrent Assets Other and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | 0.59 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from Biohaven Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biohaven Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. At this time, Biohaven Pharmaceutical's Selling General Administrative is very stable compared to the past year. As of the 17th of May 2024, Enterprise Value is likely to grow to about 3.2 B, though Tax Provision is likely to grow to (1.3 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 1.4M | 1.4M | 6.9M | 7.3M | Cost Of Revenue | 91.7M | 1.4M | 3.4M | 3.2M |
Biohaven Pharmaceutical fundamental ratios Correlations
Click cells to compare fundamentals
Biohaven Pharmaceutical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Biohaven Pharmaceutical fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 344.3M | 111.5M | 142.1M | 661.8M | 513.2M | 347.2M | |
| Other Current Liab | 52.1M | 27.1M | 37.2M | 79.3M | 36.5M | 38.6M | |
| Total Current Liabilities | 66.2M | 29.9M | 41.9M | 90.0M | 55.4M | 49.1M | |
| Total Stockholder Equity | (7.4M) | 16.8M | 34.7M | 538.8M | 428.0M | 449.4M | |
| Property Plant And Equipment Net | 8.2M | 13.6M | 18.2M | 52.4M | 48.6M | 51.0M | |
| Net Debt | (316.7M) | 185.0M | 550.7M | (174.3M) | (218.8M) | (207.9M) | |
| Retained Earnings | (972.4M) | (1.7B) | (2.6B) | (91.1M) | (499.3M) | (524.3M) | |
| Accounts Payable | 14.1M | 2.8M | 4.8M | 10.7M | 15.6M | 10.0M | |
| Cash | 316.7M | 82.5M | 76.1M | 204.9M | 249.7M | 151.5M | |
| Non Current Assets Total | 16.0M | 21.7M | 47.2M | 74.8M | 70.8M | 40.6M | |
| Non Currrent Assets Other | 7.8M | 1.0M | 3.2M | 2.6M | 2.4M | 4.2M | |
| Cash And Short Term Investments | 316.7M | 82.5M | 76.1M | 465.3M | 383.1M | 270.2M | |
| Liabilities And Stockholders Equity | 344.3M | 111.5M | 142.1M | 661.8M | 513.2M | 347.2M | |
| Non Current Liabilities Total | 285.5M | 4.8M | 5.4M | 33.0M | 29.8M | 55.3M | |
| Other Current Assets | 11.6M | 10K | 2.1M | 19.3M | 45.7M | 47.9M | |
| Other Stockholder Equity | 83.5M | 98.9M | 169.7M | 13.9M | 39.8M | 73.8M | |
| Total Liab | 351.7M | 34.7M | 47.4M | 123.0M | 85.2M | 91.0M | |
| Total Current Assets | 328.3M | 89.8M | 94.8M | 587.0M | 442.4M | 306.6M | |
| Common Stock | 881.4M | 1.2B | 1.7B | 615.7M | 887.5M | 970.6M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Biohaven Stock analysis
When running Biohaven Pharmaceutical's price analysis, check to measure Biohaven Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biohaven Pharmaceutical is operating at the current time. Most of Biohaven Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biohaven Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biohaven Pharmaceutical's price. Additionally, you may evaluate how the addition of Biohaven Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Biohaven Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.90) | Return On Assets (0.65) | Return On Equity (1.34) |
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.